000220.KS
Yuyu Pharma, Inc. [000220.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000220.KS Stock Summary
Top 10 Correlated ETFs
000220.KS
Top 10 Correlated Stocks
000220.KS
In the News
000220.KS Financial details
Company Rating
Buy
Market Cap
81.67B
Income
-7.54B
Revenue
137.34B
Book val./share
-
Cash/share
-
Dividend
105
Dividend %
2.06%
Employees
344
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.06
Forward P/E
-
PEG
-0.16
P/S
0.61
P/B
0.74
P/C
-
P/FCF
-4.96
Quick Ratio
-
Current Ratio
1.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-466.34
EPS next Y
-
EPS next Q
-
EPS this Y
362.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
10.82%
Revenue Q/Q
-0.37%
EPS Q/Q
-23.38%
-
-
-
-
SMA20
16.17%
SMA50
6.08%
SMA100
0.98%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-7%
ROC
-
Gross Margin
37%
Oper. Margin
-
Profit Margin
-5%
Payout
-
Shs Outstand
16.35M
Shs Float
10.54M
-
-
-
-
Target Price
-
52W Range
4160.0-6880.0
52W High
-26.31%
52W Low
+21.88%
RSI
56.49
Rel Volume
1.12
Avg Volume
364.08K
Volume
408.03K
Perf Week
-0.39%
Perf Month
15.23%
Perf Quarter
-9.14%
Perf Half Y
-12.89%
-
-
-
-
Beta
0.614
-
-
Volatility
190.11%, 332.95%
Prev Close
-3.24%
Price
5070
Change
3.15%
000220.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.6K | 7.27K | 7.9K | 7.25K | 8.38K | |
| Net income per share | 319.5 | 378 | 194.34 | -57.67 | -266.9 | |
| Operating cash flow per share | 485.58 | 1.06K | -215 | 282.51 | -375.68 | |
| Free cash flow per share | -314.68 | 356.11 | -1.37K | -140.5 | -711.47 | |
| Cash per share | 2.19K | 1.93K | 1.65K | 3.15K | 1.86K | |
| Book value per share | 6.82K | 7.1K | 9.21K | 7.79K | 7.05K | |
| Tangible book value per share | 6.77K | 7.09K | 9.12K | 7.8K | 7.22K | |
| Share holders equity per share | 6.82K | 7.1K | 9.21K | 7.79K | 7.05K | |
| Interest debt per share | 2.25K | 2.3K | 1.75K | 2.59K | 2.52K | |
| Market cap | 64.49B | 70.9B | 90.62B | 124.64B | 103.13B | |
| Enterprise value | 64.73B | 70.99B | 90.25B | 113.54B | 116.57B | |
| P/E ratio | 16.04 | 15.01 | 37.56 | -135.44 | -23.3 | |
| Price to sales ratio | 0.78 | 0.78 | 0.92 | 1.08 | 0.74 | |
| POCF ratio | 10.55 | 5.38 | -33.95 | 27.64 | -16.56 | |
| PFCF ratio | -16.29 | 15.94 | -5.34 | -55.59 | -8.74 | |
| P/B Ratio | 0.75 | 0.8 | 0.79 | 1 | 0.88 | |
| PTB ratio | 0.75 | 0.8 | 0.79 | 1 | 0.88 | |
| EV to sales | 0.78 | 0.78 | 0.92 | 0.98 | 0.84 | |
| Enterprise value over EBITDA | 7.88 | 6.44 | 9.68 | 15.87 | 20.38 | |
| EV to operating cash flow | 10.59 | 5.38 | -33.81 | 25.18 | -18.71 | |
| EV to free cash flow | -16.35 | 15.96 | -5.32 | -50.64 | -9.88 | |
| Earnings yield | 0.06 | 0.07 | 0.03 | -0.01 | -0.04 | |
| Free cash flow yield | -0.06 | 0.06 | -0.19 | -0.02 | -0.11 | |
| Debt to equity | 0.32 | 0.3 | 0.17 | 0.32 | 0.34 | |
| Debt to assets | 0.2 | 0.2 | 0.13 | 0.2 | 0.2 | |
| Net debt to EBITDA | 0.03 | 0.01 | -0.04 | -1.55 | 2.35 | |
| Current ratio | 2.48 | 1.53 | 3.5 | 3.29 | 1.5 | |
| Interest coverage | 4.75 | 4.52 | 3.57 | 1.22 | 0.27 | |
| Income quality | 1.42 | 2.37 | -1.11 | -4.9 | 1.41 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Payout ratio | 0.34 | 0.31 | 0.63 | -2.01 | -0.46 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.04 | 0.03 | 0.04 | |
| Research and developement to revenue | 0.02 | 0.01 | 0.04 | 0.03 | 0.06 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -1.65 | -0.66 | 5.35 | -1.5 | 0.89 | |
| Capex to revenue | -0.12 | -0.1 | -0.15 | -0.06 | -0.04 | |
| Capex to depreciation | -4.73 | -2.8 | -3.66 | -1.5 | -1.11 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7K | 7.77K | 6.35K | 3.18K | 6.5K | |
| ROIC | 0.04 | 0.06 | 0.03 | 0.04 | 0.01 | |
| Return on tangible assets | 0.03 | 0.03 | 0.02 | 0 | -0.02 | |
| Graham Net | 485.05 | 95.62 | 754.71 | 987.2 | -130.02 | |
| Working capital | 41.08B | 22.56B | 46.07B | 68.87B | 32.04B | |
| Tangible asset value | 85.17B | 88.57B | 113.2B | 124.55B | 119.66B | |
| Net current asset value | 20.52B | 17.88B | 26.6B | 34.59B | 24.53B | |
| Invested capital | 0.32 | 0.3 | 0.17 | 0.32 | 0.34 | |
| Average receivables | 24.54B | 23.3B | 20.46B | 21.38B | 24.11B | |
| Average payables | 6.76B | 5.72B | 5.84B | 7.13B | 12.41B | |
| Average inventory | 17.6B | 16.32B | 20.35B | 24.46B | 32.53B | |
| Days sales outstanding | 112.08 | 84.66 | 73.83 | 72.29 | 66.52 | |
| Days payables outstanding | 43.47 | 52.65 | 36.51 | 46.62 | 67.57 | |
| Days of inventory on hand | 134.24 | 140.3 | 163.6 | 130.93 | 169.91 | |
| Receivables turnover | 3.26 | 4.31 | 4.94 | 5.05 | 5.49 | |
| Payables turnover | 8.4 | 6.93 | 10 | 7.83 | 5.4 | |
| Inventory turnover | 2.72 | 2.6 | 2.23 | 2.79 | 2.15 | |
| ROE | 0.05 | 0.05 | 0.02 | -0.01 | -0.04 | |
| Capex per share | -800.26 | -699.32 | -1.15K | -423.01 | -335.8 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.05K | 2.1K | 2.07K | 2.16K | 0 | |
| Net income per share | -99.46 | -108.93 | 27.63 | -218 | 0 | |
| Operating cash flow per share | -160.58 | -128.86 | -51.34 | -349.96 | 0 | |
| Free cash flow per share | -194.4 | -255.3 | -131.86 | -451.18 | 0 | |
| Cash per share | 2.17K | 1.86K | 1.65K | 1.65K | 0 | |
| Book value per share | 7.05K | 7.05K | 6.86K | 7.3K | 0 | |
| Tangible book value per share | 7.14K | 7.22K | 7.04K | 7.49K | 0 | |
| Share holders equity per share | 7.05K | 7.05K | 6.86K | 7.3K | 0 | |
| Interest debt per share | 2.43K | 2.35K | 2.58K | 2.94K | 0 | |
| Market cap | 94.75B | 103.13B | 98.16B | 79.97B | 0 | |
| Enterprise value | 98.2B | 116.57B | 114.5B | 100.88B | 0 | |
| P/E ratio | -14.3 | -14.27 | 53.56 | -5.78 | 0 | |
| Price to sales ratio | 2.78 | 2.97 | 2.86 | 2.34 | 0 | |
| POCF ratio | -35.43 | -48.27 | -115.31 | -14.4 | 0 | |
| PFCF ratio | -29.27 | -24.36 | -44.9 | -11.17 | 0 | |
| P/B Ratio | 0.81 | 0.88 | 0.86 | 0.69 | 0 | |
| PTB ratio | 0.81 | 0.88 | 0.86 | 0.69 | 0 | |
| EV to sales | 2.88 | 3.36 | 3.34 | 2.95 | 0 | |
| Enterprise value over EBITDA | 166.52 | 95.85 | 8.29 | 152.68 | 0 | |
| EV to operating cash flow | -36.72 | -54.56 | -134.51 | -18.17 | 0 | |
| EV to free cash flow | -30.33 | -27.54 | -52.37 | -14.09 | 0 | |
| Earnings yield | -0.02 | -0.02 | 0 | -0.04 | 0 | |
| Free cash flow yield | -0.03 | -0.04 | -0.02 | -0.09 | 0 | |
| Debt to equity | 0.34 | 0.34 | 0.36 | 0.4 | 0 | |
| Debt to assets | 0.21 | 0.2 | 0.21 | 0.23 | 0 | |
| Net debt to EBITDA | 5.84 | 11.05 | 1.18 | 31.64 | 0 | |
| Current ratio | 1.65 | 1.5 | 1.45 | 2.03 | 1.99 | |
| Interest coverage | -0.72 | 0.4 | 1.09 | -0.42 | 0 | |
| Income quality | 1.61 | 1.18 | -1.86 | 1.75 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.35 | 0.03 | 0.37 | |
| Research and developement to revenue | 0.06 | 0.08 | 0.08 | 0.08 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
| Capex to operating cash flow | 0.21 | 0.98 | 1.57 | 0.29 | 0 | |
| Capex to revenue | -0.02 | -0.06 | -0.04 | -0.05 | 0 | |
| Capex to depreciation | -0.44 | -1.6 | -1.03 | -1.11 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.97K | 4.16K | 2.07K | 5.98K | 0 | |
| ROIC | 0 | 0 | 0.01 | 0 | -0.01 | |
| Return on tangible assets | -0.01 | -0.01 | 0 | -0.02 | -0.01 | |
| Graham Net | 285.46 | -130.02 | -449.41 | -524.44 | 0 | |
| Working capital | 37.24B | 32.04B | 30.24B | 50.79B | 46.82B | |
| Tangible asset value | 118.86B | 119.66B | 116.66B | 118.89B | 120.8B | |
| Net current asset value | 27.81B | 24.53B | 21.67B | 22.76B | 18.31B | |
| Invested capital | 0.34 | 0.34 | 0.36 | 0.4 | 0 | |
| Average receivables | 25.63B | 25.69B | 24.99B | 24.72B | 12.38B | |
| Average payables | 10.73B | 13.32B | 15.97B | 14.96B | 6.9B | |
| Average inventory | 30.53B | 36.04B | 42.46B | 47.05B | 24.5B | |
| Days sales outstanding | 68.71 | 65.57 | 64.75 | 65.13 | 0 | |
| Days payables outstanding | 43.79 | 67.74 | 70.79 | 57.32 | 0 | |
| Days of inventory on hand | 130.72 | 170.34 | 198.18 | 203.49 | 0 | |
| Receivables turnover | 1.31 | 1.37 | 1.39 | 1.38 | 0 | |
| Payables turnover | 2.06 | 1.33 | 1.27 | 1.57 | 0 | |
| Inventory turnover | 0.69 | 0.53 | 0.45 | 0.44 | 0 | |
| ROE | -0.01 | -0.02 | 0 | -0.03 | -0.02 | |
| Capex per share | -33.81 | -126.45 | -80.52 | -101.22 | 0 |
000220.KS Frequently Asked Questions
What is Yuyu Pharma, Inc. stock symbol ?
Yuyu Pharma, Inc. is a KR stock and trading under the symbol 000220.KS
What is Yuyu Pharma, Inc. stock quote today ?
Yuyu Pharma, Inc. stock price is $5070 today.
Is Yuyu Pharma, Inc. stock public?
Yes, Yuyu Pharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 364.08K
- Market Capitalization 81.67B
- Employee 344
- CEO Mr. Wonsang Yu
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.yuyu.co.kr 
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.
